Mukka Proteins financials

·FMCG & RetailChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹490cr+186.7% on Q1 FY26
Net profit
₹18.6cr+1,072.7% on Q1 FY26
EBITDA margin
9.8%+1.3 pts on Q1 FY26
EPS
₹0.63+1,160.0% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue490171+186.7%
EBITDA48.014.6+229.7%
EBITDA margin9.8%8.5%+1.3 pts
Profit before tax28.32.8+909.4%
Net profit18.61.6+1,072.7%
EPS₹0.63₹0.05+1,160.0%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹490 crNet profit₹18.6 crNet margin3.8%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024
740———
12.912.93.194.4
29.729.715.812.2
768768450362
1,525———
1,7681,4491,0061,380
—+44.0%−27.1%—
14811594.9105
8.4%7.9%9.4%7.6%
13098.081.393.1
74.157.148.174.3
4.2%3.9%4.8%5.4%
₹2.30₹1.74₹1.55₹2.34
—+12.1%−33.7%—
—−111−112−150
—−121−20.0−15.6
−232−232−132−166
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MUKKA₹24.68

Mukka Proteins Limited

· FMCG & Retail
₹ CrorePeersNARMADAKSEMcap ₹740 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization———740.4
- Cash, Equiv & ST Investments94.43.112.912.9
+ Minority Interest12.215.829.729.7
+ Total Debt362.3450.3767.8767.8
Enterprise Value———1,525.0
Revenue1,379.81,006.41,449.51,768.3
Growth %, YoY—-27.1+44.0—
EBITDA105.594.9114.6148.0
Margin %7.649.437.918.37
EBIT93.181.398.0129.9
Net Income74.348.157.174.1
Margin %5.394.783.944.19
EPS, Adj (current shares)2.341.551.742.30
Growth %, YoY—-33.7+12.1—
Cash from Operations-150.4-111.9-111.3—
Capital Expenditures-15.6-20.0-120.5—
Free Cash Flow-166.0-132.0-231.8-231.8
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Mukka Proteins financials and key ratios

Prices at the previous close · figures from the company's filings with NSE

Mukka Proteins (NSE: MUKKA) had a market capitalisation of ₹740 crore at the previous close (₹24.68 a share), a PE ratio of 10.7 on the last four quarters' profit and a price-to-book ratio of 1.48. In FY26 its consolidated net profit was ₹52.1 crore on revenue of ₹1,449 crore; in Q1 FY27 (April–June 2026) it was ₹18.9 crore. Its debt-to-equity ratio was 1.45 on 31 March 2026. Promoters held 73.33% of the shares on 30 September 2026.

Mukka Proteins Q1 FY27 results
filed 12 August 2026
Share price used
₹24.68 · previous close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Mukka Proteins at a glance · consolidated

Market cap
₹740 Crat ₹24.68 · previous close
PE ratio (last 4 quarters)
10.714.2 on FY26 profit
Price to book (PB)
1.48book value ₹16.64 a share
ROE (FY26)
11.1%unchanged vs FY25ROCE 18.9%
Debt to equity
1.45net debt ₹707 Cr
Promoter holding
73.33%unchanged vs 30 Jun 202630 September 2026
Net worth
₹499 Cr+13.2% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹232 Cr
EPS (FY26)
₹1.74

Questions

What is the Mukka Proteins PE ratio today?

Mukka Proteins' PE ratio is 10.7 at the previous close (₹24.68 a share): a market capitalisation of ₹740 crore divided by consolidated net profit of ₹69.1 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹52.1 crore) it is 14.2.

What is the Mukka Proteins debt to equity ratio?

Mukka Proteins' debt-to-equity ratio was 1.45 on 31 March 2026: borrowings of ₹768 crore against total equity of ₹529 crore. A year earlier, on 31 March 2025, it was 0.99.

What is the Mukka Proteins net worth?

Mukka Proteins' net worth — shareholders' equity in its consolidated balance sheet — was ₹499 crore on 31 March 2026, up 13.2% from ₹441 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹740 crore at the previous close.

What is the Mukka Proteins PB ratio (price to book value)?

Mukka Proteins' price-to-book (PB) ratio is 1.48 at the previous close: a market capitalisation of ₹740 crore divided by shareholders' equity (book value) of ₹499 crore on 31 March 2026. That is a book value of ₹16.64 per share against a share price of ₹24.68.

What is the Mukka Proteins ROE and ROCE?

In FY26, Mukka Proteins' return on equity (ROE) was 11.1% and its return on capital employed (ROCE) was 18.9%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 11.1% and ROCE 18.4%.

What is the Mukka Proteins book value per share?

Mukka Proteins' book value per share was ₹16.64 on 31 March 2026: shareholders' equity of ₹499 crore divided by the 30 crore shares in issue, up 14.0% from ₹14.60 a year earlier. The share price at the previous close was ₹24.68.

What is the Mukka Proteins market cap?

Mukka Proteins' market capitalisation was ₹740 crore at the previous close: 30 crore shares at ₹24.68 each.

Is Mukka Proteins debt free?

No. Mukka Proteins had borrowings of ₹768 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 1.45. Its cash and current investments were ₹60.4 crore, so its net debt was ₹707 crore.

What is the Mukka Proteins EPS?

Mukka Proteins' basic earnings per share (EPS) were ₹1.74 in FY26, against ₹1.55 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹2.31.

What is the Mukka Proteins promoter holding?

Promoters held 73.33% of Mukka Proteins on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.

What is the Mukka Proteins free cash flow?

In FY26, Mukka Proteins generated ₹111 crore of cash from operations and spent ₹121 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹232 crore. In FY25 it was −₹132 crore.

When are the Mukka Proteins next results?

Mukka Proteins has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.

What is the Mukka Proteins shareholding pattern?

On 30 September 2026, Mukka Proteins' shares were held by promoters 73.33%, foreign portfolio investors (FII/FPI) 1.70%, domestic institutions (DII) 0.20% and retail and other non-institutional investors 24.77%. Over the year, FII holding was unchanged and DII holding was down 1.46 percentage points from 1.66%.

How does Mukka Proteins compare with its peers?

On FY26 consolidated figures, against Narmada Agrobase and KSE: Mukka Proteins' operating margin of 6.8% is the second highest of the three (Narmada Agrobase 6.1%, KSE 6.9%; peer average 6.5%); its return on equity of 11.1% is the second highest of the three (Narmada Agrobase 6.7%, KSE 24.1%; peer average 15.4%).

Mukka Proteins vs Narmada Agrobase: how do they compare?

In FY26, Mukka Proteins earned net profit of ₹52.1 crore on revenue of ₹1,449 crore, against ₹3.9 crore on ₹78.4 crore for Narmada Agrobase. Mukka Proteins' operating margin was 6.8% (Narmada Agrobase 6.1%) and its return on equity 11.1% (Narmada Agrobase 6.7%).

What are the Mukka Proteins latest quarterly results?

Mukka Proteins' latest results are for Q1 FY27 (April–June 2026), filed on 12 August 2026: consolidated net profit ₹18.9 crore; revenue from operations ₹490 crore, up 186.7% year on year.

What is the Mukka Proteins revenue and profit in FY26?

In FY26 (April 2025–March 2026), Mukka Proteins' consolidated net profit was ₹52.1 crore, up 12.1% from ₹46.5 crore in FY25, on revenue from operations of ₹1,449 crore (up 44.0%).

Where do these Mukka Proteins figures come from?

From Mukka Proteins' own consolidated results, balance sheets and shareholding patterns filed with NSE. Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.